In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $1.38 in the prior trading day, Acumen Pharmaceuticals Inc (NASDAQ: ABOS) closed at $1.46, up 5.80%. In other words, the price has increased by $5.80 from its previous closing price. On the day, 0.62 million shares were traded. ABOS stock price reached its highest trading level at $1.5999 during the session, while it also had its lowest trading level at $1.41.
Ratios:
Our goal is to gain a better understanding of ABOS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.02 and its Current Ratio is at 8.02. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.19.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Citigroup on June 17, 2025, initiated with a Buy rating and assigned the stock a target price of $4.
On July 26, 2024, Citigroup started tracking the stock assigning a Buy rating and target price of $7.
On December 12, 2023, Deutsche Bank started tracking the stock assigning a Buy rating and target price of $8.Deutsche Bank initiated its Buy rating on December 12, 2023, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 23 ’25 when Zuga Matt sold 28,902 shares for $1.72 per share. The transaction valued at 49,633 led to the insider holds 231,744 shares of the business.
Zuga Matt sold 4,364 shares of ABOS for $6,986 on Jan 21 ’25. The CFO & Chief Business Officer now owns 260,646 shares after completing the transaction at $1.60 per share. On Jan 21 ’25, another insider, OConnell Daniel Joseph, who serves as the Chief Executive Officer of the company, sold 12,619 shares for $1.59 each. As a result, the insider received 20,102 and left with 667,488 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABOS now has a Market Capitalization of 88437168 and an Enterprise Value of -30930800.
Stock Price History:
The Beta on a monthly basis for ABOS is 0.15, which has changed by -0.5479876 over the last 52 weeks, in comparison to a change of 0.16821623 over the same period for the S&P500. Over the past 52 weeks, ABOS has reached a high of $3.49, while it has fallen to a 52-week low of $0.86. The 50-Day Moving Average of the stock is 18.20%, while the 200-Day Moving Average is calculated to be -8.45%.
Shares Statistics:
The stock has traded on average 443.65K shares per day over the past 3-months and 457560 shares per day over the last 10 days, according to various share statistics. A total of 60.57M shares are outstanding, with a floating share count of 44.20M. Insiders hold about 27.03% of the company’s shares, while institutions hold 58.49% stake in the company. Shares short for ABOS as of 1752537600 were 1505384 with a Short Ratio of 3.39, compared to 1749772800 on 2677418. Therefore, it implies a Short% of Shares Outstanding of 1505384 and a Short% of Float of 3.35.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The current rating of Acumen Pharmaceuticals Inc (ABOS) is the result of assessments by 3.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$0.61, with high estimates of -$0.48 and low estimates of -$0.7.
Analysts are recommending an EPS of between -$1.81 and -$2.6 for the fiscal current year, implying an average EPS of -$2.27. EPS for the following year is -$1.68, with 3.0 analysts recommending between -$1.65 and -$1.75.
